Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Exon 20 Insertion Mutations”

53 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 53 results

Testing effectiveness (Phase 2)UnknownNCT04063462
What this trial is testing

Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 60
Testing effectiveness (Phase 2)Looking for participantsNCT06864624
What this trial is testing

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC

Who this might be right for
NSCLC
Tang-Du Hospital 27
Large-scale testing (Phase 3)Looking for participantsNCT05973773
What this trial is testing

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Who this might be right for
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Taiho Oncology, Inc. 272
Testing effectiveness (Phase 2)Looking for participantsNCT05315700
What this trial is testing

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Who this might be right for
Solid Tumors
ORIC Pharmaceuticals 350
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07229339
What this trial is testing

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

Who this might be right for
Lung Non-Squamous Non-Small Cell Carcinoma
Jonsson Comprehensive Cancer Center 16
Not applicableStudy completedNCT05207423
What this trial is testing

A Chart Review Study of Adults With Advanced NSCLC

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Takeda 179
Testing effectiveness (Phase 2)WithdrawnNCT04576208
What this trial is testing

Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Takeda
Testing effectiveness (Phase 2)Study completedNCT03727724
What this trial is testing

Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
The Netherlands Cancer Institute 37
Not applicableLooking for participantsNCT06247826
What this trial is testing

Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

Who this might be right for
Non-small Cell Lung CancerEGFR Exon 20 Insertion Mutation
Groupe Francais De Pneumo-Cancerologie 30
Testing effectiveness (Phase 2)UnknownNCT04974879
What this trial is testing

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Qingdao Central Hospital 20
Large-scale testing (Phase 3)Active Not RecruitingNCT05607550
What this trial is testing

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Who this might be right for
Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung CancerEGFR Exon 20 Mutations
ArriVent BioPharma, Inc. 398
Large-scale testing (Phase 3)Active Not RecruitingNCT04129502
What this trial is testing

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Who this might be right for
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Takeda 354
Testing effectiveness (Phase 2)Looking for participantsNCT06192849
What this trial is testing

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Who this might be right for
Non Small Cell Lung CancerEGFR Exon 20 Insertion Mutation
Juan LI, MD 20
Testing effectiveness (Phase 2)UnknownNCT05132777
What this trial is testing

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung CancerEGFR Exon20 Insertion Mutations
Shanghai JMT-Bio Inc. 155
Not applicableWithdrawnNCT05863819
What this trial is testing

A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Takeda
Large-scale testing (Phase 3)Not Yet RecruitingNCT05767892
What this trial is testing

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Who this might be right for
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Suzhou Puhe Pharmaceutical Technology Co., LTD 350
Testing effectiveness (Phase 2)Looking for participantsNCT06706713
What this trial is testing

Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerEGFR Exon 20 Insertion Mutation
BeBetter Med Inc 200
Early research (Phase 1)UnknownNCT04448379
What this trial is testing

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc. 48
Testing effectiveness (Phase 2)Looking for participantsNCT06043817
What this trial is testing

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Who this might be right for
Non-Small Cell Lung CancerNSCLCEGFR/HER2 Exon 20 Insertion Mutation
Pierre Fabre Medicament 251
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Load More Results